Pharmaceuticals, Biotechnology and Life Sciences
The U.S. Food and Drug Administration (FDA) has accepted Mylan’s Biologics License Application (BLA) for multiple types of cancer treatment MYL-1401H, a proposed biosimilar to Amgen’s Neulasta. This is the second BLA accepted for review by FDA as part of the Mylan and Biocon partnership within the past two months.
Alexion Pharmaceuticals’s revenues for 2016 increased 18% compared to the previous year, bringing $3.1 billion, and that’s with a negative impact of foreign currency of 3% or $74 million, bringing net income of $399 million, way up from $144 million last year.
Boston-based pharmaceutical company Rhythm has secured $41 million through mezzanine financing round to funds its melanocortin-4 receptor for the phase 3 study.
Premier Veterinary Group’s subsidiary, Premier Vet Alliance (“PVA”), has signed the third co-operation agreement since its entry to the US market in May 2016.
The U.S. Food and Drug Administration (FDA) has approved Valeant Pharmaceuticals’s Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis.
Swedish Orphan Biovitrum (Sobi) has elected to add a novel product candidate (rFIXFc-XTEN) for the potential treatment of haemophilia B to the company’s collaboration agreement with Bioverativ.
e-Therapeutics’s Executive Director & Company Secretary Sean Nicolson is leaving the company in order to focus on other business commitments.
Denovo Biopharma’s new clinical center in China opened last year will play a very important role in the biomarker driven DB102 trial, as the company has submitted the IND application to the China FDA.
Active Biotech has reported net loss of € 1,6 million for Q4, which is decrease of loss comparing to the same period 2015 when the net loss was € 4,3 million.
Weifa ASA, Norwegian health company has reported net income of € 0,9 million for Q4 2016 which is increase comparing to the same period last year when the comapany had € 0,3 million loss. The company has more than tripled its net income for year 2016. It has reported € 2,03 million for whole 2016 and net income for the 2015 was € 0,65 million.